Not intended for the UK Apecotrep (BI 764198) is a potential first-in-class, oral, selective TRPC6 inhibitor being investigated as a novel, ...

In a multicenter, phase 2 trial across 31 centers in 10 countries, apecotrep (BI 764198) reduced proteinuria by 40% over 12 ...

Arbutus Biotech (ABUS) heads to a key March Moderna LNP patent trial as imdusiran HBV milestones drive value—get the latest ...

Not intended for the UK Apecotrep (BI 764198) is a potential first-in-class, oral, selective TRPC6 inhibitor being investigated as a novel, targeted, non-immunosuppressive therapy in people with prima ...

FinQuery, a market leader in AI-powered accounting automation, today announced the appointments of Jacob Fabbri as Chief Marketing Officer (CMO) and Michael Gerson as Senior Vice President of Customer ...

Pfizer Inc. (NYSE:PFE) Q4 2025 Earnings Call Transcript February 3, 2026 Pfizer Inc. beats earnings expectations. Reported ...

Enzeevum, a biosimilar to Eylea, is approved in Canada for multiple retinal conditions, expanding treatment options for ophthalmologists. Biosimilars may offer cost-effective alternatives, potentially ...

Advances in structure-activity relationship studies, computational modeling, and rational combination strategies are accelerating progress toward clinical development. Inconsistencies in clinical ...

Dr. James McCaffrey presents a complete end-to-end demonstration of linear regression with pseudo-inverse training implemented using JavaScript. Compared to other training techniques, such as ...

Novo Nordisk NVO and Aspect Biosystems announced that they are advancing their partnership into a new phase focused on developing next-generation cellular medicines for diabetes. The companies have ...

What FM Nirmala Sitharaman announced on infrastructure, banking, health, education and tourism. Follow The Hindu for more ...